Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger
Salarius Pharmaceuticals priced a $7 million underwritten public offering, with closing contingent on its merger with Decoy Therapeutics. The deal includes common shares, pre-funded warrants, and fixed-price Series A and B warrants. Shares plunged up to 51% Tuesday after the financing news, then rebounded over 50% pre-market and up to 65% intraday today. The merger is expected to close around November 12, 2025.
